Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
leronlimab + regorafenib
- Development stage
- Discontinued
- Lead developer
- CytoDyn
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
**Leronlimab + regorafenib** is an experimental combination therapy being studied in metastatic colorectal cancer. Leronlimab is a humanized monoclonal antibody that acts as a CCR5 antagonist, preventing the CCR5 receptor from facilitating tumor invasion, metastasis, and immune system evasion. Regorafenib is an oral small molecule multikinase inhibitor targeting kinases involved in tumor angiogenesis, oncogenesis, and the tumor microenvironment. The combination is designed to target both immune evasion (through CCR5 blockade) and tumor growth/angiogenesis (via kinase inhibition), and entered phase 2 clinical trials for patients with microsatellite stable, CCR5-positive metastatic colorectal cancer[1][3].
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)CCR5 (C-C chemokine receptor type 5)FGFR1 (Fibroblast growth factor receptor 1)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)PDGFRA (Platelet-derived growth factor receptor alpha)
Beyond the preview
Go deeper on leronlimab + regorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on leronlimab + regorafenib.